Brachytherapy

Papers
(The TQCC of Brachytherapy is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)
ArticleCitations
PPP03 Presentation Time: 10:48 AM43
BP02 Presentation Time: 4:09 PM33
Thursday, July 11, 20249:00 AM - 10:00 AMGPP01 Presentation Time: 9:00 AM32
Thursday, July 11, 20244:00 PM - 5:00 PM MPP01 Presentation Time: 4:00 PM19
PHSOR06 Presentation Time: 9:25 AM19
PO024918
PO032417
PO042516
MPP02 Presentation Time: 4:09 PM15
PPP02 Presentation Time: 10:39 AM14
BP08 Presentation Time: 5:03 PM14
PO041713
A new way to visualize prostate brachytherapy needles using ultrasound color Doppler and needle surface modifications13
PO022713
3D-printed radiopaque episcleral plaques with radioactive collimating cavities for enhanced dose delivery in brachytherapy13
Effects of pain management using nonsteroidal anti-inflammatory drug suppositories during brachytherapy for cervical cancer: A single-center prospective observational study12
P010512
PHSOP2  Presentation Time: 9:05 AM12
GPP03  Presentation Time: 9:33 AM12
After ASCENDE-RT: Biochemical and survival outcomes following combined external beam radiotherapy and low-dose-rate brachytherapy for high-risk and unfavourable intermediate-risk prostate cancer, a po11
Factors associated with late local failure and its influence on survival in men undergoing prostate brachytherapy11
Editorial Board11
Biochemical outcome of prostate cancer patients treated with hypofractionated external radiation and a single high-dose-rate brachytherapy boost11
PO4710
Low-Dose-Rate versus High-Dose-Rate intracavitary brachytherapy in cervical cancer - Final Results of a Phase III randomized trial10
PSOR12  Presentation Time: 5:25 PM10
PO3510
PSOR8  Presentation Time: 12:05 PM10
PO9310
Editorial Board10
PSOR03  Presentation Time: 12:10 PM9
PO02349
PO04219
PL02 Presentation Time: 1:45 PM9
Impact of MRI-based planning in transperineal interstitial brachytherapy for locally advanced cervix tumors: Clinical, dosimetric and toxicity outcomes9
Evaluation of variability in applicator position and organs at risk dose in fractionated intracavitary brachytherapy for cervical cancer9
Clinical outcomes of adaptive intracavitary and interstitial brachytherapy technique in locally advanced cervical cancer: A real-world data9
MSOR11 Presentation Time: 8:50 AM9
HDR and PDR brachytherapy for facial nonmelanoma skin cancer: Outcome and toxicity assessment for 155 patients8
P03018
Exclusive Ru-106 brachytherapy for the management of a recurrent corneo: Conjunctival squamous cell carcinoma8
Author Index8
PPP04  Presentation Time: 10:57 AM8
PRPP05  Presentation Time: 11:06 AM8
Determination of the optimal time for planning SAVI brachytherapy for APBI8
Masthead7
PSOR02  Presentation Time: 4:35 PM7
PO207
Table of Contents7
American Brachytherapy Society (ABS) rectoprostatic gel spacer consensus statement7
PL02  Presentation Time: 1:45 PM7
PO217
Sunday, June 19, 202211:30 AM - 12:30 PMGSOR13  Presentation Time: 11:30 AM7
MSOR12 Presentation Time: 8:55 AM7
Quantifying geometric and dosimetric advantage from the use of rectal spacing in HDR prostate brachytherapy7
PP05  Presentation Time: 5:06 PM7
Comparison of novel shielded nasopharynx applicator designs for intracavitary brachytherapy7
Masthead7
PO106
PP02  Presentation Time: 9:10 AM6
MSPP03  Presentation Time: 4:20 PM6
Is hemi-gland focal LDR brachytherapy as effective as whole-gland treatment for unilateral prostate cancer?6
The case for risk-stratified IORT for early breast cancer6
PO46  Presentation Time: 4:45 PM6
Cs-131 prostate brachytherapy boost and effect of hydrogel rectal spacer on long-term patient-reported rectal bleeding and bowel quality of life6
Radical trachelectomy and adjuvant vaginal brachytherapy to preserve fertility in pediatric cervical adenocarcinoma6
PHSOR05  Presentation Time: 12:50 PM6
High-dose-rate brachytherapy for airway malignancy a single institution experience6
GSOR14  Presentation Time: 11:35 AM6
Novel portable apparatus for outpatient high-dose-rate (HDR) brachytherapy in penile cancer6
Table of Contents6
PHSOR04  Presentation Time: 12:45 PM6
GSOR04  Presentation Time: 12:15 PM5
GPP06  Presentation Time: 11:15 AM5
Comment on “How accurate is applicator reconstruction in HDR gynecological brachytherapy? Patient-specific results from an electromagnetic tracking system designed to intercept errors before radiation5
Toward 3D-TRUS image-guided interstitial brachytherapy for cervical cancer5
PO01195
PO04245
Brachytherapy for favorable prognostic prostate cancer in men up to 60 years of age: Long term follow-up5
Partial breast irradiation: An updated consensus statement from the American brachytherapy society5
Increasing global access to brachytherapy: The ABS 300 in 10 initiative and ongoing international efforts5
I-125 eye-plaque seed economics: To re-use or to not re-use? A single institutional cost savings analysis of re-using I-125 radioactive seeds for eye—Plaque brachytherapy5
PO02425
Randomized trial comparing hypnosis versus standard management on patient anxiety and pain during pelvic brachytherapy applicator removal5
MSOP03  Presentation Time: 8:10 AM5
GSOR13  Presentation Time: 12:30 PM5
PSOR02 Presentation Time: 11:35 AM5
On the value of an EM tracking quality assurance system for pretreatment verification of needle digitization accuracy in ultrasound-based prostate HDR brachytherapy5
PO02415
Skin Posters PO07015
PO01095
MSOP06  Presentation Time: 8:25 AM5
MPP02  Presentation Time: 4:09 PM5
The NorCal brachytherapy waste audit: A simple, validated, toolkit for clinician led waste reduction5
Impact of the COVID-19 pandemic on brachytherapy and cancer patient outcomes: A systematic review5
PHSOR06  Presentation Time: 12:55 PM4
PO03204
Intra-operative process efficiency for in-room MRI-guided combined intracavitary/interstitial brachytherapy for cervical cancer4
PRPP02  Presentation Time: 10:39 AM4
PRSOP08  Presentation Time: 12:05 PM4
MSOR11 Presentation Time: 5:50 PM4
The influence of time and implants in high-dose rate image-guided adaptive brachytherapy for locally advanced cervical cancer4
PO194
PO154
The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle4
Improving efficiency and reducing costs of MRI-Guided prostate brachytherapy using Time-Driven Activity-Based costing4
GSOR09 Presentation Time: 12:10 PM4
PO02614
Wound complications and local recurrence do not differ when using interstitial brachytherapy versus external beam radiation therapy for soft tissue sarcoma4
GPP04  Presentation Time: 9:42 AM4
PO02204
Thursday, July 11, 20244:00 PM - 5:30 PM BP01 Presentation Time: 4:00 PM4
PP02  Presentation Time: 10:09 AM4
PO1144
US-guided EM tracked system for HDR brachytherapy: A first in-men randomized study for whole prostate treatment4
A primer on time-driven activity-based costing in brachytherapy4
PO01104
Thursday, June 22, 20233:30 PM - 4:30 PMPP01  Presentation Time: 3:30 PM4
Are outcomes of locally advanced cervical cancer associated with prebrachytherapy hemoglobin values and transfusion practice? An observational study comparing two large academic centres with divergent4
PRSOP03  Presentation Time: 11:40 AM4
Rule-based AI automated adaptive treatment planning for image guided cervical cancer brachytherapy4
PPP05 Presentation Time: 11:06 AM4
P03044
Targeting the GTV in medically inoperable endometrial cancer using brachytherapy4
PO914
US-guided versus US-assisted tandem insertion for cervical cancer: A nomenclature proposal4
The association of vagina equivalent dose in 2Gy fraction (EQD2) to late vagina toxicity in patients of cervical cancer treated with WPRT plus IGABT4
A general framework to develop a radiomic fingerprint for progression-free survival in cervical cancer3
Improving plan quality in cervical brachytherapy using a simple knowledge-based prediction tool for OAR dose (D2cm3)3
Prospective validation of a machine learning model for applicator and hybrid interstitial needle selection in high-dose-rate (HDR) cervical brachytherapy3
Feasibility of balloon rectal spacer implantation in HDR and LDR brachytherapy for prostate cancer treatment3
GSOR10 Presentation Time: 12:15 PM3
A novel dose-based intra-preplan method for high-dose-rate brachytherapy in cervical cancer using modeling and optimization algorithms3
PP05  Presentation Time: 11:36 AM3
PO33  Presentation Time: 10:30 AM3
Targeting prostate lesions on multiparametric MRI with HDR brachytherapy: Optimal planning margins determined using whole-mount digital histology3
Intraoperative radiation and electronic brachytherapy in Brachytherapy: A look back and forward3
PO863
PO523
How do you do it?: Gynecologic brachytherapy best practices at high volume institutions within the United States and Canada3
Dosimetric evaluation of a novel modular cell irradiation platform for multi-modality in vitro studies including high dose rate brachytherapy3
PP04  Presentation Time: 9:47 AM3
PO03113
Dosimetric characterization and experimental validation for a low-kV FPXS electronic brachytherapy system3
Multipurpose ultrasound-based prostate phantom for use in interstitial brachytherapy3
Laminaria tent insertion in preplanning MRI for CT-based cervical cancer brachytherapy3
Author Index of the Abstracts of the 2022 American Brachytherapy Society Annual Meeting3
PSOR3  Presentation Time: 11:40 AM3
Dosimetric evaluation of iodine-125 brachytherapy for brain tumors using MR guidance combined with a three-dimensional non co-planar template3
Four-fraction ultra-accelerated minimal breast irradiation in early breast cancer: The initial feasibility results of an institutional experience3
Role of the gel spacer in safely delivering whole pelvic radiation therapy without central shielding in computed tomography-based image-guided adaptive brachytherapy for uterine cervical cancer patien3
Masthead3
PO04083
MSOR9 Presentation Time: 5:40 PM3
Demographic and clinical factors associated with variations in opioid administration using conscious sedation during HDR brachytherapy for cervical cancer3
Clinical and dosimetric outcomes of a 3-fraction high-dose-rate brachytherapy boost for the treatment of locally advanced cervical cancer in a safety net hospital3
PO40  Presentation Time: 4:45 PM3
PO533
PSOR7  Presentation Time: 12:00 PM3
Detection of failure patterns using advanced imaging in patients with biochemical recurrence following low-dose-rate brachytherapy for prostate cancer3
PSA: Declining utilization of prostate brachytherapy2
PO02292
PP04  Presentation Time: 11:27 AM2
Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and HDR brachytherapy boost in cervical cancer2
Table of Contents2
PO03142
Percutaneous interstitial brachytherapy ablation for targeting oligometastatic gynecologic cancers2
GSOR02  Presentation Time: 11:35 AM2
Brachytherapy for rectal and anal cancer: Where are we and current perspectives?2
PO1122
PPP03  Presentation Time: 10:48 AM2
Table of Contents2
MSOR7 Presentation Time: 5:30 PM2
Ten-year treatment complication outcomes of radical prostatectomy vs external beam radiation vs brachytherapy for 1503 patients with intermediate risk prostate cancer2
Table of Contents2
PSOR06  Presentation Time: 12:25 PM2
PHSOR08  Presentation Time: 1:05 PM2
PO042
PO27  Presentation Time: 7:40 AM2
Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer2
Combined operative and radiotherapeutic treatment for locally recurrent gynaecologic cancer with pelvic wall invasion: A monocentric retrospective study2
Definitive treatment for primary urethral cancer: A single institution's experience with organ-preserving brachytherapy2
GSOR20  Presentation Time: 12:05 PM2
PL03 Presentation Time: 2:00 PM2
GYN Posters PO012
P03072
PO01112
GSOR06 Presentation Time: 5:25 PM2
Masthead2
PO03102
PO04062
P01142
PO04282
GSOR23  Presentation Time: 12:20 PM2
Saturday, July 13, 202410:30 AM - 11:30 AM GPP01 Presentation Time: 10:30 AM2
EM tracking with conventional CT tables: Quantifying and correcting for electromagnetic field distortion2
Editorial Board2
MSS11  Presentation Time: 4:35 PM2
Gastrointestinal and genitourinary toxicity following high dose rate vaginal cuff brachytherapy for endometrial cancer2
Outcomes and comparison of dosimetric parameters between intracavitary (Fletcher) and combined intracavitary/interstitial (Utrecht) brachytherapy in locally advanced cervical cancer2
Systematic review of brachytherapy for symptom palliation2
PO322
PP02  Presentation Time: 8:29 AM2
MPP05  Presentation Time: 4:36 PM2
GSOR12 Presentation Time: 5:55 PM2
Comparing long-term sexual dysfunction across different uterine cancer treatment modalities2
PO822
PO122
PRSOP09  Presentation Time: 12:10 PM2
Sigmoid dose accumulation and reporting for multifractionated brachytherapy for cervical cancer: Methodological development of sigmoid points through virtual endoscopic method2
PO02332
Uncertainty in magnetic resonance imaging-based prostate postimplant dosimetry: Results of a 10-person human observer study, and comparisons with automatic postimplant dosimetry2
Haralick texture feature analysis for Monte Carlo dose distributions of permanent implant prostate brachytherapy2
PO02472
GSOR06  Presentation Time: 11:55 AM2
Surgically targeted radiation therapy versus stereotactic radiation therapy: A dosimetric comparison for brain metastasis resection cavities2
Letter to the editor regarding “Reducing dose to rectum by placement of a rectum-emptying tube in cervical cancer patients treated with brachytherapy”2
Patient-specific cylinder templates for hybrid interstitial vaginal brachytherapy: Feasibility of automated 3-D design, 3D printing, and dosimetric outlook2
PO102
PL04  Presentation Time: 2:15 PM2
PHSOP6  Presentation Time: 9:25 AM2
What is appropriate target delineation for MRI-based brachytherapy for medically inoperable endometrial cancer?2
MSPP05  Presentation Time: 4:40 PM2
PO492
PO02582
Actinium-225 Targeted Agents: Where Are We Now?2
Masthead1
Radiation dose rate variations in different measurement scenarios after prostate 125I brachytherapy1
Friday, June 17, 20222:30 PM - 3:30 PM PHSPP01  Presentation Time: 2:30 PM1
MSOR7  Presentation Time: 5:15 PM1
PO1061
PO02021
PPP01  Presentation Time: 4:00 PM1
GSOR03  Presentation Time: 11:40 AM1
PO02401
PO28  Presentation Time: 7:40 AM1
A feasibility study of utilizing a cadaveric training model for novel robotic bladder cancer brachytherapy techniques1
GSOR05  Presentation Time: 12:20 PM1
PSA outcomes and late toxicity of single-fraction HDR brachytherapy and LDR brachytherapy as monotherapy in localized prostate cancer: A phase 2 randomized pilot study1
GPP06  Presentation Time: 10:00 AM1
P01061
P01111
BP04 Presentation Time: 4:27 PM1
Long-term disease-free survival following salvage brachytherapy for recurrent pediatric rhabdomyosarcoma: Two case reports and review of relevant literature1
PO051
PO1031
PO171
P01171
GPP02  Presentation Time: 9:24 AM1
PO01021
0.73082518577576